All In Biotech

Drug Trial Radar · NCT00319566

Heart and Estrogen-Progestin Replacement Study (HERS)

Last checked: Nov 19, 2026Latest source record: Apr 27, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,430 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,430

Actual

Start

Jul 1992

Primary completion

Not stated

Study completion Jul 2001

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Apr 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Prevention
Who can join
Female only, from 55 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.

Conditions

  • Coronary Heart Disease

Interventions

  • Premarin .625 mg daily plus medroxyprogesterone 2.5 mg dailyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myocardial Infarction
  2. CHD Death

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.